Phase I Study of Allogeneic Transforming Growth Factor-beta Receptor Type 2 Knockout CD70 CAR NK Cells in Treatment Refractory Clear Cell Renal Cell Carcinoma

Testing an investigational cancer therapy called TGFBR-2 KO CD70 CAR NK cell therapy.

Trial Details

NCT ID
NCT07072234
Phase
PHASE1
Sponsor
M.D. Anderson Cancer Center
Status
RECRUITING
Cancer Type
Kidney Cancer
Interventions
  • Lymphodepleting chemotherapy
  • Dexamethasone
  • Fludarabine
  • Cyclophosphamate
  • TGFBR-2 KO CD70 CAR NK
Locations (sample)
  • Houston, Texas, United States|29.76328,-95.36327

Key Eligibility Criteria

  • Eligibility Criteria
  • Participants must have histologically confirmed ccRCC that is metastatic or unresectable and for which standard curative or palliative measures do …
  • Confirmation of CD70 expression ≥ 10% by immunohistochemistry staining of the participants primary renal tumor or a metastatic lesion biopsy specim…
  • Participants must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diamet…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Kidney Cancer Trials on Trialify →